Authors

Latest:

Dr Skoulidis on the Methods of Analyzing KRAS G12C Inhibitor Efficacy in NSCLC

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.

Filip Janku, MD, PhD

Latest:

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Filipa Lynce, MD

Latest:

Dr Lynce on Ongoing Trials Evaluating Novel Combinations in Inflammatory Breast Cancer

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Filippo Pietrantonio, MD

Filippo Pietrantonio, MD, is a medical oncologist and head of the Gastrointestinal Oncology Unit at Fondazione IRCCS Istituto Nazionale dei Tumori.

Latest:

Dr Pietrantonio on Future Directions of Evaluating Amivantamab in CRC

Filippo Pietrantonio, MD, highlights the future directions of assessing amivantamab with or without chemotherapy in patients with colorectal cancer.

Fiona McCaughan, RN, MS

Latest:

Facilitating Intraperitoneal Chemotherapy Completion

Fiona McCaughan on Nurses Facilitating Intraperitoneal Chemotherapy Completion

Floor J. Backes, M

Latest:

Dr. Backes on Pelvic Exenteration Surgery in Gynecologic Cancer

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

Floortje J. Backes, MD

Floortje J Backes, MD, is a gynecologic oncologist and a professor in the College of Medicine at The Ohio State University Wexner Medical Center and the OSUCCC – James.

Latest:

Ongoing Research to Watch in Ovarian Cancer

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.

Forrest Thompson, MD

Latest:

Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer

Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.

Fortunato Ciardiello, MD, PhD, Second University of Naples

Fortunato Ciardiello, MD, PhD, Seconda Universita di Napoli

Frances Valdes-Albini, MD

Latest:

Dr. Valdes-Albini Discusses Trials in HER2+ Breast Cancer

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.

Francesca Gay, MD, PhD

Latest:

Dr Gay on Efficacy Findings From the IsKia Trial in Multiple Myeloma

Francesca Gay, MD, PhD, discusses the safety and efficacy findings derived from the phase 3 IsKia trial in patients with newly diagnosed multiple myeloma.

Francesco Forconi, MD

Latest:

Dr. Francesco Forconi on Questions That Remain Regarding Inhibiting the B-cell Receptor in CLL

Francesco Lo-Coco, MD

Latest:

Dr. Francesco Lo-Coco on Arsenic Trioxide in APL

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in acute promyelocytic leukemia (APL).

Francine Foss, MD

Latest:

Dr Foss on the FDA Approval of Denileukin Diftitox for CTCL

Francine Foss, MD, discusses the FDA approval of denileukin diftitox for the treatment of patients with CTCL.

Francis B. Palumbo, PhD, JD

Latest:

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

Francis J. Giles, MD

Latest:

ASH Interview Series

The December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.

Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center

Latest:

Future Considerations for the Treatment of R/M HPV-Positive HNSCC

Panelists discuss how emerging areas in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) research include novel immunotherapy combinations, biomarker development for treatment selection, targeted therapies against new molecular pathways, and strategies to overcome resistance to existing treatments.

Francis Yao, MD

Latest:

Dr. Yao on Transplants Beyond Milan Criteria for Liver Cancer

Francis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.

Francisco Cervantes, MD, PhD

Latest:

Dr. Cervantes Discusses COMFORT-II Long-Term Data

Francisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.